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Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm
Transformation of hematopoietic cells depends on the acquisition of genetic events leading to cytokine independence, typically associated with acquisition of an autocrine cytokine loop or/and increased expression or/and mutation of JAK genes. 1 Rearrangement of the JAK2 gene, which presumably alters JAK2 transcription, is reported in hematopoietic cells. 2 Murine models of myeloproliferative neoplasms (MPN) demonstrated that the polycythemia vera (PV) phenotype requires the combination of high expression and activation of Jak2. 3 Indeed, expression of both wild-type (WT) and mutant JAK2 transcripts can be high in PV. 4 PV is characterized by a high frequency of the JAK2 46/1 (GGCC) haplotype (represented in Figure 1A ) predisposing to the JAK2V617F mutation. 5, 6 The JAK2V617F mutation facilitates the acquisition of homozygous status for the JAK2V617F by mitotic homologous recombination (HR) occurring between the JAK2WT and JAK2V617F alleles, resulting in chromosome 9p uniparental disomy (9pUPD). 7, 8 Here we report 2 cases where high JAK2 mRNA expression was associated with a novel early step in MPN development, HR preceding JAK2 mutation. Patients Na1061 and Na1253 presented with a high hematocrit, slightly elevated leukocyte counts, normal (Na1061) or elevated (Na1253) platelet counts, aquagenic pruritus, absence of splenomegaly, and presence of JAK2V617F (20.7% for Na1061, 30.0% for Na1253), and were diagnosed with PV (see supplemental Table 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Sequencing and allele-specific qPCR analysis in granulocyte DNA of marker rs12343867 (C/T) in intron 14 of JAK2, characteristic of the 46/1 haplotype, revealed rs12343867 ratios sharply different from JAK2V617F ratios: 80% C-alleles for Na1061 and 100% T-alleles for Na1253 ( Figure 1B-C) . For both patients, CD3 ϩ lymphocytes were unambiguously heterozygous for rs12343867 ( Figure 1C ). This indicated granulocyte acquisition of homozygosity for rs12343867 but not for the V617F mutation. In other words, the acquisition of homozygosity for rs12343867 must have preceded JAK2 mutation in these patients. This was confirmed by further analysis of JAK2 in granulocytes and CD3 ϩ lymphocytes ( Figure 1C) , and of chromosome 9p using SNP arrays ( Figure 1D ). These studies showed that the DNA regions recombined involved JAK2 exons 6-25 for Na1061, and the complete 46/1 haplotype for Na1253. Moreover, SNP array studies revealed the presence of 1 subclone for Na1253 (28.24 Mb) or 2 subclones for Na1061 (5.7 and 24.54 Mb) with partial 9pUPD (supplemental Figures 2-3 and Figure 1E ). Sequencing of the complete JAK2 cDNA excluded any mutation other than V617F.
These first cases of HR of JAK2WT led us to propose a new model for MPN: the 46/1 haplotype may predispose carriers to diverse alteration of JAK2 including early HR of wild-type JAK2, associated or not with mutation in JAK2 or other genes important for myelopoiesis, the V617F mutation facilitating additional HR involving the JAK2V617F-mutated allele, leading to 9pUPD and JAK2V617F homozygosity ( Figure 1E -F). The new model allows that a nonidentified somatic genetic event may facilitate JAK2 recombination and subsequent genetic alterations eventually leading to PV phenotype ( Figure 1F ).
In the context of inherited gene mutations, meiotic HR can increase expression of the gene involved. 9 In the case of JAK2, mitotic HR could result in a configuration that amplifies JAK2 expression and subsequently cell growth after activation of Jak2 by cytokine receptors. This is of importance because MPN progenitors produce Jak2-activating cytokines. 10 For both patients, cDNA quantitative analysis revealed high JAK2 mRNA levels with Ͼ 96% JAK2V617F (see supplemental Table 2 ), implying an mRNA expression almost 100-fold higher for recombined alleles in V617F/V617F cells than for alleles in WT/WT cells. Finally, finding recurrent JAK2 recombination associated with high mRNA expression suggests that residual JAK2V617F disease may be best assessed in cDNA. Black arrows indicate the chronology of events, as deduced from the rs12343867 and V617F allelic ratios. For both patients the distortion of SNP allelic differences because of homologous recombination was higher at the telomeric end than in the centromeric region of chromosome 9p indicating 2 distinct partial 9pUPDs for Na1061 and 1 partial 9pUPD for Na1253. For both patients, SNP allelic distortion revealed pre-JAK2 homologous recombination (in purple).
(F) Main and new pathogenic models for polycythemia vera and other MPN. The current model states that MPN patients carry or acquire a predisposition to MPN and mutation in the JAK2 gene; the JAK2 GGCC haplotype is one such genetic predisposition. In other patients, another genetic abnormality, congenital or acquired, presumably in a myeloid progenitor, is responsible for clonality, growth advantage and eventually, acquisition of JAK2 mutation -V617F being the most frequent -and MPN phenotype. Because high JAK2V617F loads are usually acquired via 9pUPD and most frequent in PV, acquisition of the PV phenotype is assumed to result from 9pUPD facilitated by JAK2V617F. Both JAK2 mutation and 9pUPD may occur more than once, leading to the development of one or several JAK2V617F-homozygous subclone(s). Disease phenotype and evolution, and occurrence of 9pUPD, may vary depending on parallel genetic events (eg, TET2 mutations) and the type of JAK2 mutation (eg, high mutant loads and 9pUPD are rare in patients with JAK2 exon 12 mutations). The new model adds an early step to the conventional model, stating that subsets of patients carrying the JAK2 GGCC haplotype may be predisposed to homologous recombination (HR) of JAK2 associated with growth advantage, followed or not by mutation in the JAK2 gene on the recombined allele and high JAK2 mRNA expression. Early JAK2 HR is compatible with all of the later steps leading to MPN according to the conventional pathogenic model:
JAK2 mutation, 9pUPD, acquisition of parallel events in genes other than JAK2. The new model allows that a non-identified genetic event may facilitate JAK2 recombination and subsequent genetic alterations eventually leading to PV phenotype. To the editor:
Differential expression of MMP-2 and MMP-9 activity in megakaryocytes and platelets
In the May 31, 2011 online issue of Blood, Cecchetti et al presented a transcriptome analysis of matrix metalloproteinase (MMP) expression in megakaryocytes and platelets. 1 Their results demonstrate that megakaryocytes and platelets differentially express mRNAs and proteins for MMPs. The authors found that platelets constitutively expressed MMP-2 protein and released it on thrombin activation, although platelets lacked mRNA for MMP-2. On the other hand, they did not detect pro-MMP-9 protein in both inactivated and thrombin-stimulated platelet lysates, even though MMP-9 mRNA was present; moreover, the authors also detected MMP activity in megakaryocyte releasates but not in their lysates. The data are incongruent with previous quantitative studies and the peculiar subcellular localization in platelets of both zymogen and activated forms of MMP-9 (also named Gelatinase B). [2] [3] [4] [5] Cecchetti et al suggested several hypothesis for this unclear discrepancy/variance: (1) MMP-9 protein is secreted during pro-platelet formation in lieu of being retained in mature platelets, (2) the lack of MMP-9 proenzyme is due to more efficient platelet preparations (clearing CD45 ϩ leukocytes and thus limiting the MMP-9 contamination).
Although no MMP zymogram was displayed by the authors, we believe that there could be a simpler explanation for the incongruence with the literature data, evidencing a neglected methodologic aspect. Cecchetti et al performed all cell lysates with a buffer containing 1mM of EDTA and Na 3 VO 4 , chemicals with wellknown inhibitory effects on MMP activity. In fact, the Ca/Zndependent gelatinases are sensitive to and partially inhibited by the EDTA chelation activity, 6, 7 whereas orthovanadate (classic phosphotyrosine phosphatase inhibitor) has also been characterized as an MMP inhibitor (eg, for gelatinase B 8 and collagenase 9 ).
To reveal the possible partial inhibitory effect of EDTA and Na 3 VO 4 on platelet gelatinases, in Figure 1 we show all gelatinolytic MMP forms present in whole cord blood 10 and in purified mature platelets according to Cecchetti et al's procedure. 1 Whole cord blood contained both MMP-2 proenzyme (at 72 kDa) and pro-MMP-9 forms (monomer at 92 kDa, and complexed forms at 130 and 225 kDa; lane standard); proforms are activable by 1mM APMA (lane 2). The EDTA/Na 3 VO 4 treatment is able to partially inhibit MMP-9 in platelets lysates; in particular, both the proenzyme and APMA-activated MMP-9 forms showed a significant reduction of gelatinolytic activity (lane 3). Our observations may at least in part explain both the incongruent "absence" of MMP-9 activity in platelet lysates (similar to collagenase inhibition, like for MMP-3), as well as the presence of MMP-9 activity in only megakaryocyte releasates or untreated culture media (but not in their lysates with EDTA/Na 3 VO 4 ).
To avoid misinterpretation and possible technical pitfalls (possibly because of the neglected peculiar MMP inhibition by EDTA/ Na 3 VO 4 ), we believe that a more careful MMP analysis in For personal use only. on April 8, 2017 . by guest www.bloodjournal.org From
